Explore the vast range of titles available.

More than 40% of patients awaiting a kidney transplant in the UK are sensitised with human leucocyte antigen (HLA) antibodies. Median time to transplantation for such patients is double that of unsensitised patients at about 74 months. Removing antibody to perform an HLA-incompatible (HLAi) living donor transplantation is perceived to be high risk, although patient survival data are limited. We compared survival of patients opting for an HLAi kidney transplant with that of similarly sensitised patients awaiting a compatible organ. From the UK adult kidney transplant waiting list, we selected crossmatch positive living donor HLAi kidney transplant recipients who received their transplant between Jan 1, 2007, and Dec 31, 2013, and were followed up to Dec 31, 2014 (end of study). These patients were matched in a 1:4 ratio with similarly sensitised patients cases listed for a deceased-donor transplant during that period. Data were censored both at the time of transplantation (listed only), and at the end of the study period (listed or transplant). We used Kaplan-Meier curves to compare patient survival between HLAi and the matched cohort. Of 25 518 patient listings, 213 (1%) underwent HLAi transplantation during the study period. 852 matched controls were identified, of whom 41% (95% CI 32–50) remained without a transplant at 58 months after matching. We noted no difference in survival between patients who were in the HLAi group compared with the listed only group (log rank p=0·446), or listed or transplant group (log rank p=0·984). Survival of sensitised patients undergoing HLAi in the UK is comparable with those on dialysis awaiting a compatible organ, many of whom are unlikely to be have a transplant. Choosing a direct HLAi transplant has no detrimental effect on survival, but offers no survival benefit, by contrast with similar patients studied in a North American multicentre cohort. UK National Health Service Blood & Transplant and Guy's & St Thomas' National Institute for Health Research Biomedical Research Centre.

AbstractObjectiveTo systematically document the patterns of war related injuries in Gaza, Palestine.DesignSurvey study of international healthcare workers, August 2024 to February 2025.SettingGaza, Palestine.Participants78 international healthcare workers deployed to Gaza.Main outcome measuresThe main outcome was the type of injuries observed by international healthcare workers during the conflict in Gaza. A Delphi informed survey was distributed through non-governmental organisation rosters and secure WhatsApp and email groups. Respondents completed the survey using contemporaneous logbooks and shift records.ResultsThe survey collected data on 12 anatomical regions, mechanisms of trauma, and general medical conditions. 78 healthcare workers reported 23 726 trauma related injuries and 6960 injuries related to weapons. The most common traumatic injuries were burns (n=4348, 18.3%), lower limb injuries (n=4258, 17.9%), and upper limb injuries (n=3534, 14.9%). Explosive injuries accounted for most of the weapon related trauma (n=4635, 66.6%), predominantly affecting the head (n=1289, 27.8%), whereas firearm injuries disproportionately affected the lower limbs (n=526, 22.6%). Healthcare workers reported 4188 people with chronic disease across 11 domains requiring long term treatment.ConclusionHealthcare workers deployed to Gaza reported an injury phenotype defined by extensive polytrauma (≥2 anatomical regions), complex blast injuries from high yield explosives, firearm related injuries to upper and lower limbs, and severe disruption to primary care and the treatment of chronic diseases. The results provide actionable insights to tailor humanitarian response and highlight the urgent need for structured, resilient clinical surveillance systems.Editor’s noteThis paper is based on research from an active war zone, where conventional research methods may be impossible to apply.

Antibody incompatible transplantation (AIT) may be an only option for highly sensitized patients. Severe form of early antibody mediated rejection (AMR) adversely affects graft survival after AIT. The aim of this study was to identify individuals at risk of AMR. We analyzed 213 living donor AITs performed at our center. Among 120 ABOi, 58 HLAi and 35 DSA + FCXM-negative cases, the rates of early AMR were 6%, 31%, and 9%, respectively ( p < 0.001). On multivariate analysis for graft loss, early AMR had a HR of 3.28 ( p < 0.001). The HLAi group had worse death-censored graft survival ( p = 0.003). In the HLAi group, Patients with aggressive variant AMR (AAMR) had greater percentage of C3d complement fixing DSA, higher baseline class I and total DSA MFI levels and B-cell FCXM RMF. C1q and C3d complement fixing DSA and strong positivity of baseline B- or T-cell FXCM as predictors of AAMR had 100% sensitivity. Early AMR is of significant clinical concern in AIT as it results in poor graft survival and is not well described in literature. An aggressive variant is characterized by massive rise in DSA levels at rejection. Baseline DSA, C1q, and C3d and baseline FCXM values can be used to risk-stratify candidates for AIT.

An increasing number of sensitized patients awaiting transplantation face limited options, leading to fatalities during dialysis and higher costs. The absence of established evidence highlights the need for collaborative consensus. Donor-specific antibodies (DSA)-triggered antibody-mediated rejection (AMR) significantly contributes to kidney graft failure, especially in sensitized patients. The European Society for Organ Transplantation (ESOT) launched the ENGAGE initiative, categorizing sensitized candidates by AMR risk to improve patient care. A systematic review assessed induction and maintenance regimens as well as antibody removal strategies, with statements subjected to the Delphi methodology. A Likert-scale survey was distributed to 53 European experts (Nephrologists, Transplant surgeons and Immunologists) with experience in kidney transplant recipient care. A rate ≥75% with the same answer was considered consensus. Consensus was achieved in 95.3% of statements. While most recommendations aligned, two statements related to complement inhibitors for AMR prophylaxis lacked consensus. The ENGAGE consensus presents contemporary recommendations for desensitization and immunomodulation strategies, grounded in predefined risk categories. The adoption of tailored, patient-specific measures is anticipated to streamline the care of sensitized recipients undergoing renal allografts. While this approach holds the promise of enhancing transplant accessibility and fostering long-term success in transplantation outcomes, its efficacy will need to be assessed through dedicated studies.

BackgroundA 3-year-old girl with clinical features of atypical HUS (complement Factor I mutation inherited from an asymptomatic mother and Factor H autoantibodies) was treated with plasma exchange, progressed to kidney failure (KF) aged 4 years, and received an en bloc kidney DCD transplant aged 8 years with primary graft non-function necessitating transplant nephrectomy at the time of transplantation. She subsequently underwent re-transplantation from her father. This is a retrospective study of electronic patient records and medical notes.Case–Diagnosis/TreatmentA 9-year-old girl received an ABO-incompatible (ABOi) living–related kidney transplant from her father with recipient and donor blood groups of O and A, respectively, with baseline recipient anti-A titers 1:128 reducing to 1:4 at the time of transplant with B lymphocyte depletion with rituximab and four sessions of immunoadsorption. Six hours post-transplant, she had recurrence of aHUS and received the first dose of eculizumab. She continues on monthly home eculizumab infusions with stable kidney allograft function and negative anti-A titers 7 years post-kidney transplantation.ConclusionsThis is the first report of a pediatric high-risk ABOi living–related kidney transplantation in whom early relapse of aHUS was successfully treated with eculizumab with good long-term patient and allograft outcome.

BackgroundAfter the major changes with regard to acute and chronic ABMR in the Banff classification initiated in 2013, there has been an improvement in diagnosing antibody-mediated rejection (ABMR) in adult studies but no data have been published in the paediatric population.MethodsWe assessed 56 paediatric kidney transplant biopsies due to kidney dysfunction in patients with donor-specific antibodies (DSA) in a retrospective single-centre study between January 2006 and March 2012. The results were compared with 2003/2007 Banff classification noting the subsequent 2017 and 2019 modifications do not change the 2013 Banff classification with regard to acute antibody-mediated rejection (apart from the addition of gene transcripts/classifiers that do not affect our analysis).ResultsFollowing the 2013 Banff classification, there were seven cases (12.5%) diagnosed with ABMR that would have been misclassified when applying the 2003/2007 classification. Evaluating the histological features of all ABMR-related cases, we report the importance of v− (intimal arteritis) and t− (tubulitis) lesions: absence of v− and t− lesions in the biopsy is related to significantly higher kidney allograft survival (OR 7.3, 95%CI 1.1–48.8, p = 0.03 and OR 5.3, 95%CI 1.2–25.5, p = 0.04 respectively). Moreover, absence of t− lesions was associated with significantly fewer rejection episodes the year after the initial biopsy (OR 5.1, 95%CI 1.4–19.8, p = 0.01).ConclusionsOur study supports that the updated 2013 Banff classification shows superior clinicopathological correlation in identifying ABMR in paediatric kidney transplant recipients. Our results can be extrapolated to the recently updated 2019 Banff classification.

Transplantation is the treatment of choice for paediatric renal recipients. However, there are increased challenges in small (<20 kg) children who have complex abnormalities of the abdominal vascular system (aorta and inferior vena cava [IVC]). In this context surgical feasibility and planning is informed by review of medical images. Conventional presentation on a computer screen demands expertise in image interpretation if the spatial associations of complex anatomy are to be fully appreciated. We assessed the feasibility and potential utility of 3D printed models of patient-specific anatomy, as a means to facilitate transplantation. We describe our management in five paediatric renal recipients with vascular anomalies (median age 7 years [IQR 4·5–13·0], median weight 18 kg [IQR 14·5–29·0]). We assessed the utility of 3D printing as a planning tool in four children with complex abnormalities (one retrospective case, three prospective cases) for whom implantation was uncertain as judged by conventional imaging. Surgically relevant donor and recipient anatomy was segmented from MRI or CT data (Mimics Medical v18.0, Materialise, Leuven, Belgium). The segmentation geometry derived from the extracted anatomical data was then exported in STL file format and physically fabricated with multimaterial, polyjet 3D printing technology (Objet500 Connex1, Objet-Stratasys). We assessed the value of models using questionnaires and geometric validation studies. Four (80%) of five children survived after one death from sepsis (with a functioning graft). At the latest median follow-up of 19 months (IQR 10·5–83·0) renal allograft survival was 100% (death censored) with a median estimated glomerular filtration rate of 55 mL/min per 1·73 m2 (IQR 45–66). We have previously classified these vascular anomolies on the basis of aortic and IVC patency (I=aorta patent, II=infrarenal segment occluded, III=suprarenal segment occluded, IV=all aorta occluded) and similarly for IVC patency (A–D). By independent questionnaire, all prospective 3D printed models were considered useful for preoperative planning, and thereby facilitated transplantation. In our retrospective proof of concept, Bland–Altman analysis found that the mean difference in vascular diameter between the printed model and segmentation geometry was −0·1 mm (95% CI −0·7 to 0·5), which was insignificant when compared with the measurement uncertainty (±0·4 mm) and the limits of surgical precision. All models showed geometrical consistency with preprinting designs and intraoperative anatomical correlation within surgical acceptance for crucial decision making. Vascular anomalies do not necessarily preclude transplantation, and a classification system could guide management. Our feasibility study of patient-specific 3D printing suggests that cases classified as sufficiently complex can benefit from this technology. Patient-specific models provide the surgical team with the full, 3D, accessible, haptic, and spatial appreciation of anatomy that is crucial in surgical decision making and planning. This technology can inform the selection of suitable anastamosis sites in the presence of anomalies and the best surgical approach for implantation of an adult-sized kidney into a small child. None.

One of the great medical successes in recent years has been the reduction in the number of patients waiting for a kidney transplant. In 2009, 7190 people were on the waiting list in the UK, and in June, 2016, this number had decreased to 5116. 1 Nevertheless, many people on the list can expect to wait for years, and many patients with end-stage renal failure are never suitable for transplantation because of comorbidities and remain instead on dialysis. As such, a substantial demand exists for dialysis access surgery; in the USA, 105 923 patients initiate haemodialysis annually 2 and in the UK, more than 4000 vascular access procedures are done each year to facilitate haemodialysis. 3 These operations are mostly to create arteriovenous fistulae, which are the recommended form of vascular access. 4

This guideline, from a European Society of Organ Transplantation (ESOT) working group, concerns the management of kidney transplant patients with HLA antibodies. Sensitization should be defined using a virtual parameter such as calculated Reaction Frequency (cRF), which assesses HLA antibodies derived from the actual organ donor population. Highly sensitized patients should be prioritized in kidney allocation schemes and linking allocation schemes may increase opportunities. The use of the ENGAGE 5 ( (Bestard et al., Transpl Int, 2021, 34: 1005–1018) system and online calculators for assessing risk is recommended. The Eurotransplant Acceptable Mismatch program should be extended. If strategies for finding a compatible kidney are very unlikely to yield a transplant, desensitization may be considered and should be performed with plasma exchange or immunoadsorption, supplemented with IViG and/or anti-CD20 antibody. Newer therapies, such as imlifidase, may offer alternatives. Few studies compare HLA incompatible transplantation with remaining on the waiting list, and comparisons of morbidity or quality of life do not exist. Kidney paired exchange programs (KEP) should be more widely used and should include unspecified and deceased donors, as well as compatible living donor pairs. The use of a KEP is preferred to desensitization, but highly sensitized patients should not be left on a KEP list indefinitely if the option of a direct incompatible transplant exists.